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SUMMARY 
Background: Administration of parenteral doses with microbial contamination can lead to 
infective morbidity or death. 
Aim: To test whether aseptic preparation of parenteral doses or additives to sterile doses 
undertaken in dedicated pharmaceutical rather than clinical environments reduces the risk of 
microbial dose contamination. 
Methods: Data identified from a systematic review were examined using random effects 
meta-analyses, and t-tests were used to compare dose contamination frequencies.  
Findings: In all, 16,552 doses from 34 studies (33 records) were identified. For all the data 
combined there was a significantly higher frequency of contamination of doses prepared in 
clinical than in pharmaceutical environments {3.7% [95% confidence interval (CI): 2.2, 6.2; 
N = 10,272 doses] vs 0.5% (95% CI: 0.1, 1.6; N = 6280 doses); P = 0.007}. Contamination of 
doses was significantly higher when prepared as individual lots than as part of a batch in 
pharmaceutical environments [2.1% (95% CI: 0.7, 5.8; N = 168 doses) vs 0.2% (95% CI: 0.1, 
0.9; N = 6112 doses); P = 0.002]. There was a significantly higher frequency of dose 
contamination if additions were made to sterile parenteral doses in clinical environments [risk 
ratio: 2.121 (95% CI: 1.093, 4.114); P = 0.026]. The overall quality of the studies was judged 















Conclusion: Reported rates of parenteral dose contamination were orders of magnitude 
higher than accepted reference standards, which may increase infection risk. The limited 
evidence on contamination rates supports dose preparation in pharmaceutical rather than 








Administration of a parenteral dose with microbial contamination may result in 
infective morbidity and death. Recent examples include: postoperative sepsis after inadequate 
aseptic handling of intravenous anaesthetic; loss of vision or further surgery due to 
endophthalmitis as a consequence of contaminated intravitreal injections in the USA; an 
outbreak of bloodstream infections requiring withdrawal of relevant stock due to 
contaminated intravenous analgesia in Taiwan; and deaths in newborns as a consequence of 
contaminated parenteral nutrition in France and the UK.1‒4 This means it is important to 
implement safe procedures in routine practice to prevent inadvertent microbial dose 
contamination. For example, the risk of contamination is expected to be lower when 
procedures are undertaken in an environment with a low density of microbes than one with a 
high density. Therefore, it is often recommended to move aseptic preparation of parenteral 
doses away from a clinical environment (with a higher density of microbes) into a specially 
designed pharmaceutical environment  [with a lower density of  microbes (and particulates)]  
in line with recognized standards operating in countries such as the USA or the UK.5‒7 For 
example, in the immediate area used to prepare parenteral medicines there could be more than 
90 times the number of colony-forming units falling on to a 90 mm diameter trypticase soy 
agar plate in a 4 h period in a clinical environment than is allowed by the standards applied to 
pharmaceutical environments in some countries.7,8 The use of a pharmaceutical environment 
is particularly important in the preparation of batch doses, which carry the risk of 
contaminating multiple lots of individual doses, and where there is likely to be a period of 
storage before administration to patients. However, since pharmaceutical environments 
meeting recognized standards for aseptic dose preparation are costly and require operational 
expertise that may not always be readily available, they are not always used. Therefore, there 















in which they are undertaken in order to obtain the desirable effects in routine clinical 
practice.  
In 2009 we published a systematic review with meta-analysis to summarize published 
frequencies of contamination of parenteral doses prepared in clinical and pharmaceutical 
environments under aseptic techniques.9 This provided some evidence favouring dose 
preparation in the pharmaceutical environment, but the conclusions were weakened by the 
small number of studies which were generally of low quality. It is possible that some earlier 
studies may have been missed because the initial review used only one database search engine 
(PubMed from 1947 onwards). Since our review, a considerable amount of new information 
has become available which needs to be incorporated into the analyses. In the meantime, 
clinical concern about methods to reduce morbidity and cost due to infections has been 
increasing. For example, an international initiative has sought to rationalize and harmonize 
standards for aseptic preparation of parenteral doses throughout Europe.10,11 It is clear that the 
existing evidence base needs to be reviewed, updated, and clarified by providing a more 
precise definition of the pharmaceutical environment.9 Therefore, the aim of this study was to 
clarify and extend the evidence base to address the following three hypotheses: one, the risk 
of infective contamination is different for aseptic preparation in a clinical and pharmaceutical 
environment; two, the risk is also different for aseptic preparation of individual and batch 
doses within the same type of environment; and three, the risk is different for additives rather 
than no additives to sterile doses prior to administration. We also sought to consider future 
research needs in light of the current evidence base. 
Methods 
The literature search was undertaken on 10 February 2014 with a wider protocol than 
that undertaken by the previous review.9 The present literature search used an additional 
search term, truncated search terms, and combination of three search terms only if more than 
5000 results were returned for any two search term combination. Three databases were used 
for all available years: Medline from 1946 onwards using OvidSP; Embase from 1947 
onwards using OvidSP; and the Cochrane Library. Attempts were made to identify further 
papers by hand searching. 
The literature search included studies that involved microbial contamination with 
bacteria and/or fungi. The studies involved preparation of doses for parenteral administration 
to patients prepared under aseptic techniques, including simulation studies. Studies were 
excluded if they were not reported in the English language, if they only involved animals, or 
if they reported the rate of contamination of infusate stock (an infusate in a single container 















contamination of multi-dose vials after repeated use). Studies were also excluded if they 
involved the use of blood or a blood component, if there was freezing/thawing of prepared 
doses, or if there was reuse of equipment during dose preparation (except when used in the 
preparation of a single batch). For an environment to qualify as a pharmaceutical environment 
the recognized standard of the cabinet in which the doses were prepared and the room in 
which that cabinet was situated had to be specified in the record (journal article). When a 
single record reported more than one outcome, for example when using different preparation 
environments, each outcome was included as a separate study. Consistent data within the 
same record were combined only if whole groups of data could be combined. 
The search terms (including variations and truncated terms) and number of results are 
shown in Table I. In brief, each of four search terms was combined with each of four further 
search terms, unless a combination returned more than 5000 results, in which case a third 
search term was added in an attempt to capture the most relevant results. It can be seen from 
Table I that a third search term was required on five occasions. Additional papers were sought 
through cross-referencing and discussion with experts in the field. 
The literature search identified 42,246 records (17,662 from Medline, 20,824 from 
Embase and 3760 from the Cochrane Library) and 28,020 after duplicates had been removed. 
The title and abstract (if necessary and accessible) of each of the 28,020 identified records 
was evaluated and excluded if it did not meet the above inclusion criteria. This left 137 
records, which were individually subjected to a full text review to confirm relevance and 
compliance with the above criteria to yield a final total of 34 studies from 33 records.8,12‒43 
Each of the final 19 studies from 17 records identified in our 2009 search were identified in 
the present search but five of those studies from four records were excluded due to inadequate 
and/or inadequately described pharmaceutical environments.9,12,14‒16,18‒22,24,33,36,43‒47 The 
methodological stages of the search are shown in Figure 1. As previously, the included studies 
were divided into groups according to whether doses were prepared in a clinical or 
pharmaceutical environment (hypothesis 1), whether doses had been prepared as individual 
lots or as part of a batch (hypothesis 2), and whether doses had been sampled without or 
before administration or during or after administration to a patient (due to a risk of 
contamination from manipulations after preparation and potential differences in time between 
preparation and sampling which may have affected recovery of damaged microbial cells).9 
Doses were considered to be either contaminated or not contaminated without any attempt to 
identify the density of any micro-organisms present; the types of micro-organisms, where 















Two of the authors (P.D.A. and K.S.H.) independently assessed the quality of the 
included studies using the GRADE system with subsequent discussion to resolve any 
disagreement.48,49 The recommendations of the UK National Health Service Centre for 
Reviews and Dissemination (CRD) and Cochrane as well as the PRISMA guidelines for 
reporting systematic reviews were considered at all stages during this review.50‒52 
Statistical analysis 
The point estimate, standard error and 95% confidence interval for the contamination 
rate of each separate group was obtained by logarithmic (logit) transformation. When there 
was zero contamination in a group, a value of 0.5 contaminated doses was used to overcome 
the mathematical difficulties associated with logarithmic transformation (the log10 of zero is 
minus infinity). Data amalgamation and the meta-analyses were undertaken using a random 
effects model and the software Comprehensive Meta Analysis version 2 (Biostat, Englewood, 
NJ, USA). One-group meta-analyses were used for hypotheses 1 and 2 and a two-group meta-
analysis was used for hypothesis 3 due to the nature of the available studies. The random 
effects model was chosen because of the clinical heterogeneity of the studies, but the I2 
statistic is also presented. Comparisons between group means were undertaken using unpaired 
t-tests, with a two-tailed P < 0.05 considered statistically significant. 
Results 
Quality of studies 
For the purpose of this review, both raters graded all of the included studies as low to 
very low quality, with three disagreements within these categories. After discussion, the 
majority of the studies were graded as low quality primarily because they were non-
randomized, and four studies were graded as very low quality primarily due to small sample 
size and limited procedural detail and high contamination rate.18,34,36,40 
Overview of the rate of contamination of doses prepared in clinical and pharmaceutical 
environments 
A grand total of 16,552 doses eligible for inclusion were identified from 34 studies 
taken from 33 records, which are summarized in Table II.8,12‒43 The single record identified 
through other sources in our previous review was identified by the present literature search.9,12 
Excluding control groups, this represents an increase of 133% in the number of doses (16,552 
vs 7101), 79% in the number of studies (34 vs 19), and 94% in the number of records (33 vs 
17) from the 2009 review.9 If the five studies not meeting the inclusion criteria of the present 
review are withdrawn from the first review, there is an increase of 173% in the number of 
doses (16,552 vs 6074), 143% in the number of studies (34 vs 14), and 154% in the number of 















Of the total 33 records, only seven involved head-to-head comparisons. One record 
compared batch doses and individual lots in a clinical environment and six records compared 
additives and no additives to sterile doses in a clinical environment.15,18,21,28,29,35 
Figure 2 shows the forest plot obtained when all the study data were combined in a 
meta-analysis grouped according to environment (pharmaceutical or clinical) and type of dose 
preparation (individual or batch). The majority (94%) of the doses that had been prepared as 
individual lots in clinical environments (N = 4141) had been sampled during or after 
administration, and all of the other doses had been sampled without or prior to administration. 
When only the 4141 doses prepared as individual lots in clinical environments were included 
there was a non-significantly higher frequency of contamination of doses sampled without or 
prior to administration than during or after administration [5.3% (95% CI: 2.7, 10.0; N = 3889 
doses) (I2 = 93.07%; P < 0.001) vs 2.3% (95% CI: 0.5, 10.1; N = 252 doses) (I2 = 56.45%; P 
= 0.101); P = 0.314]. 
Nineteen of the 22 studies with contamination reported the type of 
microbe.8,13,14,16‒19,21‒24,27‒33,35,39,41,42 In pharmaceutical environments this was limited to 
coagulase-negative staphylococci (including Staphylococcus epidermidis), Bacillus spp., and 
Propionibacterium spp.17,39 The same microbes were identified in clinical environments, 
where more pathogenic microbes were also found, including Staphylococcus aureus, Serratia 
marcescens, Klebsiella spp., Enterobacter spp., and fungi (including Candida 
spp.).13,14,16,19,21‒24,27,29‒31,33,35,42 
Hypothesis 1: dose preparation in a clinical compared to a pharmaceutical environment 
 Individual and batch doses combined 
 All identified doses. The analysis involved 16,552 doses from 34 studies (33 
records8,12‒43). Of these, 10,272 doses from 27 studies (26 records8,13‒16,18‒25,27‒33,35‒38,42,43) had 
been prepared in clinical environments and 6280 doses from seven studies (seven 
records12,17,26,34,39‒41) had been prepared in pharmaceutical environments. When all the data 
were combined there was a significantly higher frequency of contamination of doses prepared 
in clinical than in pharmaceutical environments [3.7% (95% CI: 2.2, 6.2; N = 10,272 doses) 
(I2 = 95.35%; P < 0.001) vs 0.5% (95% CI: 0.1, 1.6; N = 6280 doses) (I2 = 69.18%; P = 
0.003); P = 0.007]. The between-study contamination was more variable in the clinical than in 
the pharmaceutical environment (range: 0.1‒55.7 vs 0.0‒2.6 respectively). 
Doses sampled without or prior to administration. There were 12,663 doses from 21 
studies (21 records8,12,13,16,17,19‒21,23,25‒27,30,33,34,37‒42) that had been sampled without 
administration or prior to administration, of which 6383 doses from 14 studies (14 















from seven studies (seven records12,17,26,34,39‒41) had been prepared in pharmaceutical 
environments. When all the data were combined, there was a significantly higher frequency of 
contamination of doses prepared in clinical than in pharmaceutical environments [2.5% (95% 
CI: 1.2, 5.5; n = 6383 doses) (I2 = 95.69%; P < 0.001) vs 0.5% (95% CI: 0.1, 1.6; n = 6280 
doses) (I2 = 69.18%; P = 0.003); P = 0.044]. The between-study contamination was more 
variable in the clinical than in the pharmaceutical environment (range: 0.1‒28.4% vs 
0.0‒2.6% respectively). 
 Doses sampled during or after administration 
 It was not possible to compare doses prepared in clinical and pharmaceutical 
environments that had been sampled during or after administration due to lack of data in the 
pharmaceutical environment. 
 Individual doses 
 All identified doses. The analysis involved 4309 doses from 18 studies (18 
records14,15,17,18,21,22,24,27‒32,35‒37,40,43). Of these, 4141 doses from 16 studies (16 
records14,15,18,21,22,24,27‒32,35‒37,43) had been prepared in clinical environments and 168 doses 
from two studies (two records17,40) had been prepared in pharmaceutical environments. When 
all the data were combined, there was a non-significantly higher frequency of contamination 
of doses prepared in clinical than in pharmaceutical environments [4.7% (95% CI: 2.5, 8.4; N 
= 4141 doses) (I2 = 91.64%; P < 0.001) vs 2.1% (95% CI: 0.7, 5.8; N = 168 doses) (I2 = 
00.00%; P = 0.856); P = 0.190]. The between-study contamination was more variable in the 
clinical than in the pharmaceutical environment (range: 0.2‒55.7% vs 2.0‒2.6% respectively). 
 Doses sampled without administration or prior to administration. There were 420 
doses from five studies (five records17,27,30,37,40) that had been sampled without administration 
or prior to administration, of which 252 doses from three studies (three records27,30,37) had 
been prepared in clinical environments and 168 doses from two studies (two records17,40) had 
been prepared in pharmaceutical environments. When all the data were combined there was a 
non-significantly higher frequency of contamination of doses prepared in clinical than in 
pharmaceutical environments [2.3% (95% CI: 0.5, 10.1; N = 252 doses) (I2 = 56.45%; P = 
0.101) vs 2.1% (95% CI: 0.7, 5.8; N = 168 doses) (I2 = 00.00%; P = 0.856); P = 0.923]. The 
between-study contamination was more variable in the clinical than in the pharmaceutical 
environment (range: 0.6‒6.3% vs 2.0‒2.6% respectively). 
 Doses sampled during or after administration. It was not possible to compare doses 
prepared in clinical and pharmaceutical environments that had been sampled during or after 















 Batch doses 
All identified doses. The analysis involved 12,243 doses from 16 studies (16 
records8,12,13,16,19‒21,23,25,26,33,34,38,39,41,42). Of these, 6131 doses from 11 studies (11 
records8,13,16,19‒21,23,25,33,38,42) had been prepared in clinical environments and 6112 doses from 
five studies (five records12,26,34,39,41) had been prepared in pharmaceutical environments. When 
all the data were combined, there was a significantly higher frequency of contamination of 
doses prepared in clinical than in pharmaceutical environments [point estimate: 2.7% (95% 
CI: 1.1, 6.2; N = 6131 doses) (I2 = 96.48%; P < 0.001) vs 0.2% (95% CI: 0.1, 0.9; N = 6112 
doses) (I2 = 56.49%; P = 0.056); P < 0.001]. The between-study contamination was more 
variable in the clinical than in the pharmaceutical environment (range: 0.1‒28.4% vs 
0.0‒2.4% respectively). 
Doses sampled without or prior to administration. Since all of the identified doses had 
been sampled without or prior to administration, a comparison of doses prepared in clinical 
and pharmaceutical environments that had been sampled without or prior to administration 
yields the same results as all of the combined data (above). 
 Doses sampled during or after administration. It was not possible to compare doses 
prepared in clinical and pharmaceutical environments that had been sampled during or after 
administration due to lack of data in either the clinical or pharmaceutical environment. 
Hypothesis 2: dose preparation as individual lots or as part of a batch 
Clinical and pharmaceutical environments combined 
 All identified doses. The analysis involved 16,552 doses from 34 studies (33 
records8,12‒43). Of these, 4309 doses from 18 studies (18 records14,15,17,18,21,22,24,27‒32,35‒37,40,43) 
had been prepared as individual lots and 12,243 doses from 16 studies (16 
records8,12,13,16,19‒21,23,25,26,33,34,38,39,41,42) had been prepared as part of a batch. When all the data 
were combined there was a significantly higher frequency of contamination of doses prepared 
as individual lots than as part of a batch [4.4% (95% CI: 2.5%, 7.6%; N = 4309 doses) (I2 = 
90.77%; P < 0.001) vs 1.3% (95% CI: 0.5%, 3.0%; N = 12,243 doses) (I2 = 96.68; P < 0.001); 
P = 0.022]. The between-study contamination was more variable for doses prepared as 
individual lots than as part of a batch (range: 0.2‒55.7% vs 0.0‒28.4% respectively). 
 Doses sampled without administration or prior to administration. There were 12,663 
doses from 21 studies (21 records8,12,13,16,17,19‒21,23,25‒27,30,33,34,37‒42) that had been sampled 
without administration or prior to administration, of which 420 doses from five studies (five 
records17,27,30,37,40) had been prepared as individual lots and 12,243 doses from 16 studies (16 
records8,12,13,16,19‒21,23,25,26,33,34,38,39,41,42) had been prepared as part of a batch. When all the data 















prepared as individual lots than as part of a batch [point estimate: 2.7% (95% CI: 1.2, 6.0; N = 
420 doses) (I2 = 28.53%; P = 0.231) vs 1.3% (95% CI: 0.5, 3.0; N = 12,243 doses) (I2 = 
96.68%; P < 0.001); P = 0.231]. The between-study contamination was more variable for 
doses prepared as part of a batch than as individual lots (range: 0.0‒28.4% v 0.6‒6.3%, 
respectively). 
 Doses sampled during or after administration. It was not possible to compare doses 
prepared as individual lots and as part of a batch that had been sampled during or after 
administration due to lack of data for doses prepared as part of a batch. 
 Clinical environments 
 All identified doses. The analysis involved 10,272 doses from 27 studies (26 
records8,13‒16,18‒25,27‒33,35‒38,42,43). Of these, 4141 doses from 16 studies (16 
records14,15,18,21,22,24,27‒32,35‒37,43) had been prepared as individual lots and 6131 doses from 11 
studies (11 records8,13,16,19‒21,23,25,33,38,42) had been prepared as part of a batch. When all the 
data were combined, there was a non-significantly higher frequency of contamination of 
doses prepared as individual lots than as part of a batch [4.7% (95% CI: 2.5%, 8.4%; N = 
4141 doses) (I2 = 91.64%; P < 0.001) vs 2.7% (95% CI: 1.1%, 6.2%; N = 6131 doses) (I2 = 
96.48%; P < 0.001); P = 0.299]. The between-study contamination was more variable for 
doses prepared as individual lots than as part of a batch (range: 0.2‒55.7% vs 0.1‒28.4% 
respectively). 
 Doses sampled without or prior to administration. There were 6383 doses from 14 
studies (14 records8,13,16,19‒21,23,25,27,30,33,37,38,42) that had been sampled without or prior to 
administration, of which 252 doses from three studies (three records27,30,37) had been prepared 
as individual lots and 6131 doses from 11 studies (11 records8,13,16,19‒21,23,25,33,38,42) had been 
prepared as part of a batch. When all the data were combined, there was a non-significantly 
higher frequency of contamination of doses prepared as part of a batch than as individual lots 
[point estimate: 2.7% (95% CI: 1.1, 6.2; N = 6131 doses) (I2 = 96.48%; P < 0.001) vs 2.3% 
(95% CI: 0.5, 10.1; N = 252 doses) (I2 = 56.48%; P = 0.101); P = 0.856]. The between-study 
contamination was more variable for doses prepared as part of a batch than as individual lots 
(range: 0.1‒28.4% vs 0.6% to 6.3% respectively). 
 Doses sampled during or after administration. It was not possible to compare doses 
prepared as individual lots and as part of a batch that had been sampled during or after 
administration due to lack of data for doses prepared as part of a batch. 
 Pharmaceutical environments 
 All identified doses. The analysis involved 6280 doses from seven studies (seven 















prepared as individual lots and 6112 doses from five studies (five records12,26,34,39,41) had been 
prepared as part of a batch. When all the data were combined there was a significantly higher 
frequency of contamination of doses prepared as individual lots than as part of a batch [2.1% 
(95% CI: 0.7, 5.8; N = 168 doses) (I2 = 00.00%; P = 0.856) vs 0.2% (95% CI: 0.1, 0.9; N = 
6112 doses) (I2 = 56.49%; P = 0.056); P = 0.002]. The between-study contamination was 
more variable for doses prepared as part of a batch than as individual lots (range: 0.0‒2.4% vs 
2.0‒2.6% respectively). 
Doses sampled without or prior to administration. Since all of the identified doses had 
been sampled without or prior to administration, a comparison of doses prepared as individual 
lots and as part of a batch that had been sampled without or prior to administration yields the 
same results as all of the combined data (above). 
 Doses sampled during or after administration. It was not possible to compare doses 
prepared as individual lots and as part of a batch that had been sampled during or after 
administration, since no relevant doses that had been prepared as either individual lots or as 
part of a batch had been identified.  
Hypothesis 3: undertaking additions to terminally sterilized doses 
The maximum expected contamination rate of doses terminally sterilized according to 
appropriate and validated procedures is one per million.53 
Clinical and pharmaceutical environments combined 
 It was not possible to combine doses from clinical and pharmaceutical environments, 
since no studies that reported the contamination rate of sterile doses with and without 
additives undertaken in pharmaceutical environments had been identified. 
 Clinical environments 
The analysis involved 1723 doses from six studies (six records15,18,21,28,29,35). Of these, 
additions had been made to 1108 doses and no additions had been made to 615 doses. All of 
the doses had been prepared as individual lots and sampled during or after administration. 
Figure 3 shows the forest plot when all of the study data were combined in a meta-analysis. 
There was a significantly higher frequency of contamination of doses with additives than 
without additives [risk ratio: 2.121 (95% CI: 1.093, 4.114); P = 0.026], with a low statistical 
heterogeneity (I2 = 22.50%; P = 0.265). 
Pharmaceutical environments 
It was not possible to compare sterile doses with and without additives in 
















This update identified more than double the number of doses than the 2009 review, 
which we have attempted to summarize to help inform judgements when establishing policy 
and clinical practice that ultimately aim to reduce patient infection rates.9 Overall, the 
contamination frequency was lower when doses had been prepared in pharmaceutical than in 
clinical environments, but reported rates were often unacceptably high in both settings. For 
example, the mean reported study frequency of microbial contamination of doses prepared 
under aseptic techniques in pharmaceutical environments could be >100 times higher than 
that expected from following the procedures recommended in Europe (>2.0% compared with 
0.02%), and >2750 times higher in clinical environments than that expected in a 
pharmaceutical environment (>55.0% compared to 0.02%).11 The greater number of studies 
identified in this update meant that a previously non-significant but intuitive finding of the 
previous review achieved statistical significance in the present review (Hypothesis 3).9 
Hypothesis 1: dose preparation in a clinical compared to a pharmaceutical environment 
There was a consistently lower frequency of contamination of doses prepared in 
pharmaceutical environments compared to clinical environments. However, this finding was 
not found to be statistically significant for doses prepared as individual lots, despite up to 
more than a two-fold difference in the overall frequency of dose contamination (4.7% vs 2.1% 
for all individual doses combined, and 2.3% vs 2.1% for only those individual doses sampled 
without administration or prior to administration). This lack of statistical significance could at 
least in part be explained by the limited data identified for doses prepared as individual lots in 
pharmaceutical environments (N = 168) (a potential type 2 error due to inadequate statistical 
power), which could have been compounded by necessary mathematical corrections during 
the analyses (see limitations below). A consistently narrower range of between-study 
frequencies of dose contamination was found for doses prepared in pharmaceutical than in 
clinical environments.  
The lower frequency and variability of contamination of doses prepared in 
pharmaceutical than in clinical environments is intuitive since pharmaceutical facilities are 
constructed and operated to restrict the number of environmental microbes, incorporate 
specialized equipment operated by staff wearing special clothing to minimize shedding of 
micro-organisms (and particles) and who have more consistent and extensive training in the 
validation in the use of aseptic techniques.8 When reported, the types of micro-organisms 
found after preparation in pharmaceutical environments were generally of low pathogenicity. 
The same bacteria were reported in doses prepared in clinical environments, but a wider range 
of micro-organisms was found in this setting, including various Gram-negative bacteria and 















procedures followed in clinical environments, but the closer proximity of drug preparation to 
patients serves as an additional source of micro-organisms that are antibiotic resistant and/or 
more pathogenic. Indeed, perceived benefits of pharmaceutical rather than clinical 
environments for aseptic preparation of parenteral doses have been noted in national 
documents, such as in the UK, and particularly for high-risk products such as parenteral 
nutrition.54‒56 
In addition to potential clinical benefits it is also necessary to consider the economic 
consequences of where doses are prepared. None of the reviewed studies undertook a cost-
effectiveness analysis but the start-up costs for building a new facility to create an appropriate 
pharmaceutical environment would be high (e.g. several million national currency units in 
Europe or the USA). There are also substantial ongoing costs (including operator training, 
maintenance, monitoring for environmental contaminants, and the need for an appropriately 
qualified manager). In addition, logistic issues created by a centralized facility, such as the 
need to reallocate staff resource from wards to the pharmacy department, and the need to 
safely and efficiently deliver drugs to points of use, would have to be addressed. 
Hypothesis 2: dose preparation as individual lots or as part of a batch 
For all the doses in both clinical and pharmaceutical environments combined, 
contamination was found to be higher in doses prepared as individual lots rather than as part 
of a batch. This difference was found to be significant in pharmaceutical environments but not 
in clinical environments. It is intuitive that individual doses would be a higher risk than batch 
doses in pharmaceutical environments since the risks of batch preparation are offset by fewer 
environmental contaminants, less variable techniques, and the availability of specialized 
equipment. It is also intuitive that potential benefits of batch preparation would be lost in an 
uncontrolled environment with greater contaminants where more variable techniques are 
employed and no specialized equipment for batch production is available. These findings 
support recommendations to limit the expiry of parenteral doses prepared under aseptic 
techniques in clinical environments, for example to 24 h in the UK, which effectively 
preclude batch preparation, and which do not apply to pharmaceutical environments (although 
different additional requirements do apply).56 
Hypothesis 3: the effect of undertaking additions to terminally sterilized doses 
It is reasonable to suggest that aseptic manipulations to a sterile dose can only increase 
the risk of microbial contamination, but there is limited evidence for such an effect. Unlike 
the 2009 review, which reported no significant effect of additions to sterilized doses, this 
updated review found a significantly higher contamination rate of sterile doses subjected to 















0.026) respectively].9 This difference can be explained by use of a meta-analysis based on 
only three studies with high statistical heterogeneity (I2 = 66.45%, P = 0.055) in the 2009 
review, and a meta-analysis based on six studies with lower heterogeneity (I2 = 22.50%, P = 
0.265) in the present review.9,15,18,21,28,29,35 This finding is consistent with the intuitive idea 
that aseptic manipulations should be minimized in uncontrolled environments such as hospital 
wards whenever possible. Nevertheless, adequate protocols and training are still required 
when it is necessary to prepare doses in clinical environments under aseptic technique. The 
updated conclusion that additions to sterile doses in clinical environments increase the 
contamination rate is in line with the findings for the previous two hypotheses. 
Limitations 
 The evidence base was limited and generally based on poor quality studies, weakening 
the conclusions of this paper. One of the main limitations is that the studies did not primarily 
set out to examine the hypotheses raised in this review and so did not use the most appropriate 
study designs to address the hypotheses raised in this review. Furthermore, although there are 
substantially more studies in the current review than in the 2009 review,9 there is still the 
possibility that a type 2 error may have arisen when testing specific hypotheses. For example, 
there were only 168 individual doses prepared in pharmaceutical environments identified. The 
risk of type 2 error may have also been increased by the need to add 0.5 contaminated doses 
in a group when it in reality there were no contaminated doses. For example, the effect on the 
rate of contamination of doses prepared as individual lots in a pharmaceutical environment in 
one study was reported as 0.0% (zero contaminated doses from a total of 18 doses) but was 
included in the analyses as 2.4% (0.5 contaminated doses from a total of 18 doses).40 The 
relevance of this mathematical complication is reduced as the sample size increases. Another 
potential limitation is that the studies spanned a period of >40 years (1972 to 2013), most of 
which were more than 10 years old [79% (27 from 34 studies)], which raises the possibility 
that the overall results do not exactly reflect current practice with currently used products. 
Finally, the general lack of head-to-head trials (seven from a total of 33 records) has meant 
that in some cases less robust analyses had to be used. In standard meta-analyses involving 
head-to-head trials, the differences between two groups of individual studies are established 
and amalgamated (two group meta-analysis). By contrast, in the present work for hypotheses 
1 and 2 the average results from studies involving each group were amalgamated separately 
(one group meta-analysis) and then compared with each other. This increases the risk of bias 
since the products tested and conditions in the two comparator groups are less well matched. 
For example, 38% (3889 from 10,272) of the doses prepared in clinical environments had 















prepared in pharmaceutical environments, and 40% (4141 from 10,272) of doses prepared in 
clinical environments had been prepared as individual lots compared to 3% (168 from 6280) 
in pharmaceutical environments. 
Recommendations 
 It is logical that the safest environment should be used to prepare parenteral doses 
under aseptic technique but several high-profile incidents (including deaths) in recent years 
make the continued lack of high-quality data in this field surprising. The limited and low-
quality evidence base supports the use of pharmaceutical rather than clinical environments for 
aseptic parenteral dose preparation and does not support batch preparation in clinical 
environments, but further data are required. There is a need for high-quality head-to-head 
trials with large sample sizes to strengthen the available evidence base. Such studies would 
better inform decisions and policies in clinical practice. In particular, at the present time there 
are limited published data for doses prepared as individual lots in pharmaceutical 
environments (N = 168), and for doses prepared as individual lots in clinical environments 
without administration to patients (N = 252). In addition, the introduction of a reporting 
system for contamination rates achieved during routine clinical practice and/or routine 
simulation studies used to verify competence of operator aseptic technique that takes into 
account the sampling procedures employed would be of benefit. Future work in this area 
should also consider the risk of contamination and infection with different types of microbes, 
the clinical risks associated with contamination of different types of preparation (e.g. 
intuitively an intraocular preparation sounds higher risk than a preparation intended for bolus 
intravenous administration), and the economic implications, including cost-effectiveness, of 
drug preparation in clinical and pharmaceutical environments.  
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The terms and number of results for the literature search undertaken on February 10th, 2014 




Search terms Results 
(N) 
Medline (OvidSP) 1 (syringe or syringes).mp. or syring*.tw. 21,041 
 2 (bag or bags).mp. or bag*.tw. 18,909 
 3 (infusion or infusions).mp. or infus*.tw. 258,728 
 4 (vial or vials).mp. or vial*.tw. 6066 
 5 (microbial or microbiological).mp. or 
micro*.tw. 
2,017,452 
 6 (bacterium or bacteria).mp. or bact*.tw. 598,873 
 7 (fungus or fungi).mp. or fung*.tw. 134,157 
 8 (contaminated or contamination).mp. or 
contam*.tw. 
166,465 
 9 prepared.mp. or prep*.tw. or 
manufactured.mp. or manuf*.tw. or 
compounded.mp. or compound*.tw. 
1,110,191 
 10 (1 and 5) or (1 and 6) or (1 and 7) or (1 and 8) 
or (2 and 5) or (2 and 6) or (2 and 7) or (2 and 
8) or (3 and 5 and 9b) or (3 and 6 and 9c) or (3 
and 7) or (3 and 8) or (4 and 5) or (4 and 6) or 
(4 and 7) or (4 and 8) 
19,123 




1 (syringe or syringes).mp. or syring*.tw. 32,435 
 2 (bag or bags).mp. or bag*.tw. 30,560 
 3 (infusion or infusions).mp. or infus*.tw. 352,153 
 4 (vial or vials).mp. or vial*.tw. 10,079 
 5 (microbial or microbiological).mp. or 
micro*.tw. 
2,221,231 















 7 (fungus or fungi).mp. or fung*.tw. 252,530 
 8 (contaminated or contamination).mp. or 
contam*.tw. 
253,438 
 9 prepared.mp. or prep*.tw. or 
manufactured.mp. or manuf*.tw. or 
compounded.mp. or compound*.tw. 
1,697,262 
 10 (1 and 5) or (1 and 6) or (1 and 7) or (1 and 8) 
or (2 and 5) or (2 and 6) or (2 and 7) or (2 and 
8) or (3 and 5 and 9b) or (3 and 6 and 9c) or (3 
and 7) or (3 and 8) or (4 and 5) or (4 and 6) or 
(4 and 7) or (4 and 8) 
23,099 




#1 “syringe” or “syringes” or syring* 1364 
 #2 “bag” or “bags” or bag* 4467 
 #3 “infusion” or “infusions” or infus* 36,233 
 #4 “vial” or “vials” or vial* 1325 
 #5 “microbial” or “microbiological” or micro* 66,334 
 #6 “bacterium” or “bacteria” or bact* 25856 
 #7 “fungus” or “fungi” or fung* 2759 
 #8 “contaminated” or “contamination” or 
contam* 
3453 
 #9 “prepared” or prep* or “manufactured” or 
manuf* or “compounded” or compound* 
64,682 
 #10 (#1 and #5) or (#1 and #6) or (#1 and #7) or 
(#1 and #8) or (#2 and #5) or (#2 and #6) or 
(#2 and #7) or (#2 and #8) or (#3 and #5 and 
#9b) or (#3 and #6c) or (#3 and #7) or (#3 and 
#8) or (#4 and #5) or (#4 and #6) or (#4 and 
#7) or (#4 and #8) 
3760 
aAll document search. 
bThe combination of search terms 3 and 5 yielded 57,265 results in Medline, 33,340 results in 
Embase, and 7464 results in the Cochrane Library, and 4848, 671, and 876 results 















cThe combination of search terms 3 and 6 returned 6363 results in Medline and 9036 results in 
Embase, and 689 and 784 results respectively when search term 9 was included in the 
combination. The third search term was not required for the combination of search terms 3 
















Summary of studies that reported the frequency of microbial contamination of parenteral doses prepared under aseptic techniques in clinical and 
pharmaceutical environments 













 Control group (no 
additives) 
 



















Batch Clinical No 778c 19c  – – 
Aydin et 
al.13 
Turkey Propofol with 
and without 
lidocaine 










Individual Clinical Yes 150* 0  96 0 
Burke et 
al.16 
USA 5% w/v 
glucose 





















Individual Pharmaceutical No 150e 3e  – – 
D’Arcy et 
al.18 





Batch Clinical No 1000 9  – – 
Driver et 
al.20 
USA Various for 
obstetric 
theatre use 
Batch Clinical No 756 0  – – 
Ernerot et 
al.21,† 
Sweden Various Batch Clinical No 50 0  – – 
Ernerot et 
al.21,† 
Sweden Various Individual Clinical Yes 131* 3  40 2 
Farrington 
et al.22 
England Midazolam or 
propofol 






































Individual Clinicali No 92j 1j  – – 
Kundsin et 
al.28 
USA Not stated Individual Clinical Yesk 432* 5  247 1 
Letcher et 
al.29 
USA ‘Medications’ Individual Clinical Yes 224m,* 13m  142m 5m 
Lorenz et 
al.30 
Austria Propofol Individual Clinical Nof 80n 5n  – – 
Macias et 
al.31 

































Batch Pharmaceutical No 20 0  – – 
Poretz et 
al.35 
USA 0.9% w/v 
sodium 
chloride in 5% 
w/v glucose in 
Ringer’s 
lactate 
Individual Clinicali Yesj 110* 10  50 2 





Individual Clinical No 80r 0r  – – 
Stjernstrom 
et al.38 
Sweden ‘Saline’ and 
growth 
medium 













































Individual Clinical Yes 290* 0  – – 
*Asterisks indicate doses that were sampled during or after administration, and the absence of an asterisk indicates doses that were sampled 
without or prior to administration. 
†Different aspects examined within the same record. 
aA clinical environment includes hospital wards or operating theatres; to be classified as a pharmaceutical environment, the record must state 
compliance with a recognized standard for both the preparation cabinet and immediate room surrounding that cabinet environment. 
b
‘Yes’ if the doses were sampled during or after administration and ‘no’ if the doses were sampled without or prior to administration. 
cIn this study, 19 of 276 doses prepared by nurses were contaminated; zero of 502 doses prepared by a pharmacy operator were contaminated. 
dThe data from part 2 of this study have been excluded since they involved unacceptable methodology (a delay in drawing up the dose). 
eOf the 150 prepared doses, 52 were parenteral nutrition and all of the three contaminated doses were parenteral nutrition. 
fThese doses were administered to patients after they had been sampled. 
gThis record reports that one additional prepared dose was misplaced and not tested. 
hIncludes only those doses prepared in a standardized pharmaceutical environment. 
iOnly the data from a clinical environment are included since the nature of the pharmaceutical environment used is unacceptable/unclear. 
jExcludes data from vial residues. 
kSimulated patient administration. 















nThe data from sample 2 of group I have been excluded since they represented the same doses, and data from group II have been excluded due to 
unacceptable conditions. 
pStudy design excluded patients receiving electrolytes, antibiotics or cancer chemotherapy. 
qData reported from cases without reuse of administration sets. 
rData from sampling immediately after dose preparation, not those same doses sampled after infusion (when three contaminated samples were 
identified). 
sData from standardized pharmaceutical conditions since the environment used for the negative control doses is unclear. 
















Figure 1. The methodological stages of the literature search used to identify studies that 
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Figure 2.  
Forest plot and summary statistics of the frequency of the contamination rates of parenteral 
doses prepared aseptically in clinical and pharmaceutical environments. Asterisks indicate 
doses that were sampled during or after administration, and the absence of an asterisk 
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Figure 3. Forest plot of random effects meta-analysis comparing contamination rates of 
sterile parenteral doses with and without additives in clinical environments. Asterisks indicate 
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